Pilot: Varenicline For Nicotine Vaping Cessation In Non Smoker Vaper Adolescents
Study Details
Study Description
Brief Summary
The Investigators propose a randomized, placebo-controlled trial to test the hypothesis that varenicline added to group behavioral and texting support will be well tolerated and improve vaping cessation rates among nicotine dependent adolescents who vape, do not smoke regularly, and are willing to try treatment to stop vaping compared to placebo added to group behavioral and texting support. The study will consist of a three-arm randomized, placebo-controlled, parallel-group study of (1) varenicline up to 1 mg bid for 12 weeks added to behavioral and texting support compared with (2) behavioral and texting support and placebo and (3) monitoring only. The primary comparison will be of vaping cessation rates in those assigned to varenicline vs placebo.To do this, the investigators propose to enroll 300 adolescents aged 16-25 who meet eligibility criteria.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 4 |
Detailed Description
Enrollees will include 300 nicotine dependent adolescents aged 16-25, who vape, do not smoke, and want to quit vaping. The study will will consist of a three-arm randomized, placebo-controlled, parallel-group study of (1) varenicline up to 1 mg bid for 12 weeks added to behavioral and texting support for adolescent vaping cessation or (2) behavioral and texting support and placebo or (3) monitoring only. The primary comparison of interest is efficacy of (1) varenicline vs (2) placebo arms on vaping abstinence outcomes. The study consists of one enrollment visit, one baseline visit, twelve weekly individual treatment and assessment sessions, and six monthly visits at weeks 4, 8, 12, 16, 20 and 24 weeks. At the enrollment visit, participants will complete interviews, questionnaires and diagnostic assessments, as well as saliva and urine sample and vitals. At the baseline visit, participants will complete several interviews, questionnaires, provide a saliva sample for cotinine measurement, and be randomized to the varenicline plus behavioral treatment group, the placebo plus behavioral treatment group, or monitoring-only group. Study staff will distribute varenicline or identically appearing placebo with instructions on how to take the study medication at weeks 0, 2, 4 and 8. Participants will be instructed to bring all empty and unused study medication at each in-person study visit through Week 12. At the weekly treatment meetings, participants will participate in cognitive behavioral therapy and complete questionnaires. Monthly visits will consist of interviews, questionnaires and a saliva and urine sample.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Varenicline Participants will receive varenicline 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7 and starting on day 8, 1 mg twice daily for a total of 12 weeks added to 12 weeks of group behavioral and texting support specifically designed for teen vaping cessation |
Drug: Varenicline
varenicline: 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7 and starting on day 8, 1 mg twice daily for a total of 12 weeks
Other Names:
|
| Placebo Comparator: Placebo Participants will receive identical placebo 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7 and starting on day 8, 1 mg twice daily for a total of 12 weeks added to 12 weeks of group behavioral and texting support specifically designed for teen vaping cessation |
Drug: Placebo
Identical placebo: 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7 and starting on day 8, 1 mg twice daily for a total of 12 weeks
|
| No Intervention: Monitoring only Participants will attend weekly and monthly sessions that will only consist of assessments. No study medication, no behavioral or texting support. |
Outcome Measures
Primary Outcome Measures
- Percentage of participants with continuous nicotine vaping abstinence from week 9 through end of treatment [Weeks 9-12]
Those assigned to varenicline and group behavioral and texting support will have a higher rate of cotinine verified, continuous nicotine vaping abstinence from study week 9 to end of treatment as operationalized by self-report of no nicotine vaping since the last study visit and urinary cotinine <50 ng/ml at each study visit in the designated timeframe.
- Percentage of participants with continuous nicotine vaping abstinence from week 9 through end of follow-up [Weeks 9-24]
Those assigned to varenicline and group behavioral and texting support will have a higher rate of cotinine verified, continuous nicotine vaping abstinence from study week 9 to end of follow-up as operationalized by self-report of no nicotine vaping since the last study visit and urinary cotinine <50 ng/ml at each study visit in the designated timeframe.
- Nicotine product exposure [Baseline-week 24]
Those assigned to varenicline will have greater reduction in vaped nicotine product exposure than those assigned to placebo as determined by urine cotinine at each visit
- Onset of vaping abstinence [Baseline-24 weeks]
Those assigned to varenicline will have earlier onset of abstinence. Self-report verified by urine cotinine at each study visit.
- Latency to first lapse [Baseline-24 weeks]
Those assigned to varenicline will have longer latency to first lapse. Self-report verified by urine cotinine at each study visit.
- Latency to relapse [Baseline-24 weeks]
Those assigned to varenicline will have longer latency to relapse. Self-report verified by urine cotinine at each study visit.
- Duration of vaping abstinence [Baseline-24 weeks]
Those assigned to varenicline will have a longer duration of abstinence. Self-report verified by urine cotinine at each study visit.
- Number total number of days of vaping abstinence [Baseline-24 weeks]
Those assigned to varenicline will have greater total number of days of vaping abstinence. Total number of days vape-free by self-report verified by urine cotinine at each study visit will be compared.
Secondary Outcome Measures
- Number of adverse events during the treatment period [Baseline-week 12]
Adverse events are assessed via standardized questions prompting participants to report any changes in their physical or mental health.
- Nicotine withdrawal symptoms [Baseline-Week 12]
Symptoms will be assessed using the Minnesota Withdrawal Scale (MNWS), a 9-item self-rated scale of urge to smoke (craving); depressed mood; irritability, frustration or anger; anxiety; difficulty concentrating; restlessness; increased appetite; difficulty going to sleep; difficulty staying asleep, on an ordinal scale from 0 (not at all) to 4 (extreme). It will be administered at enrollment and each subsequent study visit.
- Intensity of nicotine craving [Baseline-week 12]
The scale used to measure intensity of craving will be a Visual Analogue Scale 0 (no desire at all) - 7 (unable to resist)
- Severity of nicotine craving [Baseline-Week12]
Severity of nicotine cravings will be assessed using the Questionnaire of Vaping Craving (QVC), a 10-item, valid and reliable measure of vaping craving that queries desire and intent to vape and anticipation of positive outcomes related to e-cigarette use, on an ordinal scale from 1 (strongly agree) to 7 (strongly disagree). It will be administered at enrollment and each subsequent study visit.
- Severity of clinical symptoms (mood and anxiety) [Baseline-week 16]
As assessed by the Mood and Anxiety Symptoms Questionnaire (MASQ-D30), is a 30-item adaptation of the 96 item MASQ that is quick, valid and reliable assessment of depression and anxiety in adolescents, with answers on a ordinal scale from Not at all/slightly to Extremely. It will be administered at each study visit to follow participants' mood symptoms over time during the intervention and follow up.
Other Outcome Measures
- Amount of substances other than nicotine consumed [Baseline-week 16]
Assessed with timeline follow back where individuals report the number of days, times, and amount of alcohol, tobacco, marijuana, and non-medical prescription drugs consumed since last study visit.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Ages 18-25 inclusive;
-
Self report of daily or near daily nicotine vaping for the prior ≥ 3 months, screening semi-quantitative urine cotinine positive for recent nicotine use, exhaled CO <10 ppm and score ≥4 on the 10-item E-cigarette Dependence Inventory (ECDI);
-
Self-report of no combusted tobacco use in the past 2 months at enrollment;
-
Total body weight at screening ≥35 kg (77 lbs) and Body Mass Index (BMI) ≤35 kg/m2;
-
Report motivation to quit vaping in the next 30 days;
-
Able to understand study procedures and read and write in English;
-
Competent and willing to consent to participate in study procedures.
Exclusion Criteria:
-
Use of a smoking cessation medication in the prior month (nicotine patch, gum, nasal spray, or inhaler, varenicline, bupropion);
-
Unwillingness to abstain during the study from using smoking cessation aids other than those provided by the study;
-
Unstable medical condition, epilepsy, severe renal impairment;
-
Evidence of active problem substance use severe enough in the investigator's opinion to compromise ability to safely participate;
-
Prior adverse drug reaction to varenicline;
-
Unwilling to provide urine samples;
-
Any condition or situation that would, in the investigator's opinion, make it unlikely that the participant could adhere safely to the study protocol.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Center for Addiction Medicine | Boston | Massachusetts | United States | 02114 |
Sponsors and Collaborators
- Massachusetts General Hospital
- National Institute on Drug Abuse (NIDA)
Investigators
- Principal Investigator: Eden Evins, MD, Massachusetts General Hospital
- Principal Investigator: Randi Schuster, PhD, Massachusetts General Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2020P002774-Pilot
- R01DA052583